

## News Release

Lonza Group Ltd  
Muenchensteinerstrasse 38  
CH-4002 Basel, Switzerland  
www.lonza.com

### **Lonza and Bio\*One Capital to invest in second large scale commercial mammalian cell culture manufacturing facility for Biopharmaceuticals in Singapore**

Basel and Singapore, 5 December 2006 - Lonza Group Ltd (SWX:LONN) and Singapore's Bio\*One Capital announce the signing of a joint venture, Lonza Biologics Tuas, to build a large-scale mammalian cell culture facility in Singapore for the manufacture of commercial biopharmaceuticals. This will be the second large-scale mammalian manufacturing plant in Singapore, and the third one globally that Lonza has built. Depending upon customer request, the capital investment will amount up to USD 350 million.

Lonza and Bio\*One Capital entered into an initial joint venture in February 2006 to build an 80,000 liter large-scale mammalian biopharmaceutical production facility named Lonza Biologics Singapore Pte Ltd. This facility became 100% owned by Lonza upon signing of the Lonza Biologics Tuas joint venture. Genentech has an exclusive option to acquire the Lonza owned facility between 2007 and 2012.

Lonza Biologics Tuas, located in Tuas Biomedical Park, will have up to four mammalian bioreactor trains, each with a flexible capacity of 1,000 up to 20,000 liters and inclusive of the respective purification units.

The plant is expected to be constructed over two phases. The construction of the Lonza Biologics Tuas shell, in the first phase, will be initiated in February 2007 and the groundbreaking ceremony will be celebrated in March 2007. The final build-out of the facility will be completed and become operational at the latest in 2011, in line with customer commitments. When fully completed, Lonza Biologics Tuas expects to hire approximately 350 people for the operation.

Stefan Borgas, CEO of Lonza, commented: "With this project Lonza continues to strengthen its leading position as the global custom manufacturer of biopharmaceuticals entering the fast growing Asian market. The facility will operate with cutting edge technology with a skilled labor force and will be able to manufacture products with a wide array of processes, yields and technologies. It will offer our customers an additional site to complement our existing large scale Portsmouth, NH USA facility, and expand upon our capabilities to serve our clients in this fast growing market segment."

"Bio\*One Capital is extremely pleased that within a very short time, the capacity of the first joint venture plant has been fully contracted out and is delighted to enter into a second joint venture plant to create sufficient capacity to keep pace with anticipated market growth," said Ms Swee-Yeok Chu, CEO of Bio\*One Capital. "With two large-scale biologics plants here, Singapore is poised to become one of the world's top manufacturing locations for biologics. This new joint venture underscores the strength of our partnership with Lonza, the unique value we offer to customers through the operations in Singapore, and Bio\*One Capital's ambitious strategy to grow our biologics portfolio."

This joint venture leverages on Singapore's strengths in sustainably competitive, highly technological and high quality manufacturing in general and the country's excellent capabilities in GMP production of bulk actives for global pharmaceutical companies specifically.

#### **About Lonza**

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life sciences industries. Its products and services extend through its customers' supply chain needs, from research and development to final product manufacture. Lonza is the global leader in the production and technical support of pharmaceutical active ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also a leading provider of value added chemical and biotech ingredients to the nutrition, hygiene, preservation, agrochemical and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2005 Lonza had sales of CHF 2.52 billion. Further information can be found at [www.lonza.com](http://www.lonza.com).

#### **About Bio\*One Capital**

Bio\*One Capital is a leading, dedicated biomedical sciences investment management company in Asia with a worldwide presence. With funds of over US\$600 million, investments are focused on promising and innovative global biomedical companies where Bio\*One Capital can play a value adding role in bridging and supporting companies' growth strategies in Asia through their operations in Singapore. A part of the Singapore Economic Development Board, Bio\*One Capital oversees a portfolio of over 60 companies in US, Europe, Singapore and Asia. For more information, please visit <http://www.bio1capital.com>

For further information:

Investor Relations/Media

Margot Connor

Tel +41 61 316 8253

Fax +41 61 316 9253

[margot.connor@lonza.com](mailto:margot.connor@lonza.com)

Media Relations

Dominik Werner

Tel +41 61 316 8798

Fax +41 61 316 9253

[dominik.werner@lonza.com](mailto:dominik.werner@lonza.com)

Bio\*One Capital

Sheo S. Rai

Tel + 65-6395-7784

Fax +65-6395-7797

[sheo\\_shanker\\_rai@bmsg.gov.sg](mailto:sheo_shanker_rai@bmsg.gov.sg)